The treatment of ocular neovascular diseases is being revolutionized by intravitreal
therapies targeting vascular endothelial growth factor (VEGF). Two agents are approved for …

Large submacular hemorrhage, an uncommon manifestation of neovascular age-related
macular degeneration, may also occur with idiopathic polypoidal choroidal vasculopathy …

Objective We aimed to compare visual and anatomical outcome in subretinal aflibercept vs.
intravitreal aflibercept in the context of Pars Plana Vitrectomy (PPV), pneumatic …

Objective To compare efficacy and safety profile of subretinal aflibercept, ranibizumab, and
bevacizumab in the context of pars plana vitrectomy, pneumatic displacement with …

Purpose: To assess the effectiveness of consecutive intravitreal injections of recombined
tissue plasminogen activator (rtPA), expansile gas and bevacizumab in eyes with acute …

Aims: To review and discuss the literature on recombinant tissue plasminogen activator
(rtPA) for the treatment of a recent-onset submacular hemorrhage in patients with age …

Aims: Retinal pharmacotherapy has gained great importance for the treatment of various
retinal diseases. An increasing number of drugs have been constantly released into the …

purpose. To study photoreceptor apoptosis and iron migration as mechanisms of
retinotoxicity in a rabbit model of subretinal hemorrhage (SRH) and to assess intravitreal …

Aim: To evaluate the efficacy and safety of pars plana vitrectomy (ppV) with subretinal
coapplication of recombinant tissue plasminogen activator (rtPA) and bevacizumab, and …

The exact incidence of submacular haemorrhage (SMH) in patients with neovascular age-
related macular degeneration (nAMD) is unknown, and risk factors for its occurrence ill …